JP2024527557A5 - - Google Patents

Info

Publication number
JP2024527557A5
JP2024527557A5 JP2023580778A JP2023580778A JP2024527557A5 JP 2024527557 A5 JP2024527557 A5 JP 2024527557A5 JP 2023580778 A JP2023580778 A JP 2023580778A JP 2023580778 A JP2023580778 A JP 2023580778A JP 2024527557 A5 JP2024527557 A5 JP 2024527557A5
Authority
JP
Japan
Prior art keywords
immune effector
effector cells
seq
binding polypeptide
antigen receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023580778A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527557A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/103070 external-priority patent/WO2023274384A1/zh
Publication of JP2024527557A publication Critical patent/JP2024527557A/ja
Publication of JP2024527557A5 publication Critical patent/JP2024527557A5/ja
Pending legal-status Critical Current

Links

JP2023580778A 2021-07-01 2022-06-30 B7h3を標的とする抗原結合ポリペプチド及びその応用 Pending JP2024527557A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110749481 2021-07-01
CN202110749481.6 2021-07-01
PCT/CN2022/103070 WO2023274384A1 (zh) 2021-07-01 2022-06-30 靶向b7h3的抗原结合多肽及其应用

Publications (2)

Publication Number Publication Date
JP2024527557A JP2024527557A (ja) 2024-07-25
JP2024527557A5 true JP2024527557A5 (cg-RX-API-DMAC7.html) 2025-07-07

Family

ID=84690474

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023580778A Pending JP2024527557A (ja) 2021-07-01 2022-06-30 B7h3を標的とする抗原結合ポリペプチド及びその応用

Country Status (10)

Country Link
US (1) US12133890B2 (cg-RX-API-DMAC7.html)
EP (1) EP4365203A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024527557A (cg-RX-API-DMAC7.html)
KR (1) KR20240027117A (cg-RX-API-DMAC7.html)
CN (1) CN115916833B (cg-RX-API-DMAC7.html)
AU (1) AU2022301099A1 (cg-RX-API-DMAC7.html)
CA (1) CA3224476A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023015153A (cg-RX-API-DMAC7.html)
WO (1) WO2023274384A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202401043B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023274380A1 (zh) * 2021-07-01 2023-01-05 宁波茂行生物医药科技有限公司 靶向IL13Rα2的通用型CAR-T细胞及其制备方法和应用
WO2024094165A1 (zh) * 2022-11-04 2024-05-10 茂行制药(苏州)有限公司 靶向b7h3的通用型car-t细胞及其制备方法和应用
TW202438527A (zh) * 2023-03-17 2024-10-01 瑞士商百濟神州瑞士有限責任公司 抗b7h3抗體以及其使用方法
WO2024240248A1 (zh) * 2023-05-24 2024-11-28 茂行制药(苏州)有限公司 用于靶向b7h3的同种异体嵌合抗原受体t细胞的给药的方法和组合物
CN118829656B (zh) * 2023-12-01 2026-04-24 苏州智核生物医药科技有限公司 B7h3结合多肽及其用途
CN117924518B (zh) * 2024-01-05 2025-08-22 苏州艾凯利元生物科技有限公司 用于nk细胞的嵌合抗原受体及工程化的nk细胞
WO2025219520A1 (en) * 2024-04-18 2025-10-23 Match Medicines Gmbh MODIFIED HUMAN T CELL WITH A REDUCED HLA-Ia REPERTOIRE AND METHOD OF PRODUCTION
WO2025255308A1 (en) * 2024-06-07 2025-12-11 Intellia Therapeutics, Inc. Cd8 co-receptor chimeric polypeptides in tcr cell therapy
WO2026120164A1 (en) * 2024-12-05 2026-06-11 Essand, Magnus Cell-based therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA315676A (en) * 1931-09-29 Schmidt Walter High grade magnesium alloy
AU2002229639A1 (en) * 2000-12-13 2002-06-24 De Haard, Johannes Joseph Wilhelmus Camelidae antibody arrays
CA2706425A1 (en) * 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
KR101763499B1 (ko) 2012-11-07 2017-07-31 화이자 인코포레이티드 항-il-13 수용체 알파 2 항체 및 항체-약물 접합체
EP3452499A2 (en) * 2016-05-06 2019-03-13 Juno Therapeutics, Inc. Genetically engineered cells and methods of making the same
JP7170666B2 (ja) * 2017-05-08 2022-11-14 プレシジョン バイオサイエンシズ,インク. 操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法
JP7621795B2 (ja) * 2017-10-19 2025-01-27 セレクティス 改善された免疫細胞療法のためのnk阻害物質遺伝子の標的指向遺伝子組み込み
WO2020010239A1 (en) * 2018-07-06 2020-01-09 The Board Of Trustees Of The Leland Stanford Junior University Chimeric antigen receptor polypeptides and methods of using same
CN113166261A (zh) * 2018-10-11 2021-07-23 印希比股份有限公司 B7h3单域抗体及其治疗性组合物
CN112390892B (zh) * 2019-08-14 2024-01-12 博源润生医药(杭州)有限公司 一种嵌合抗原受体以及表达该嵌抗原受体的免疫效应细胞
US20210128617A1 (en) 2019-08-27 2021-05-06 The Trustees Of The University Of Pennsylvania SYNTHETIC CARS TO TREAT IL13R-alpha-2 POSITIVE HUMAN AND CANINE TUMORS
CA3156761A1 (en) * 2019-10-22 2021-04-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors
JP7670358B2 (ja) 2020-01-02 2025-04-30 寧波茂行生物医薬科技有限公司 修飾された免疫エフェクター細胞及びその調製方法

Similar Documents

Publication Publication Date Title
JP2025032091A5 (cg-RX-API-DMAC7.html)
JP2024534847A5 (cg-RX-API-DMAC7.html)
JP2025028239A5 (cg-RX-API-DMAC7.html)
JP2020533958A5 (cg-RX-API-DMAC7.html)
JP2022534680A5 (cg-RX-API-DMAC7.html)
JP2018527014A5 (cg-RX-API-DMAC7.html)
IL317912A (en) A combined chimeric antigen receptor targeting CD19 and CD20 and its applications
JP2020517295A5 (cg-RX-API-DMAC7.html)
JP2022040287A5 (cg-RX-API-DMAC7.html)
JP2019523301A5 (cg-RX-API-DMAC7.html)
JP2025038057A5 (cg-RX-API-DMAC7.html)
JP2021524264A5 (cg-RX-API-DMAC7.html)
CN115916833A (zh) 靶向b7h3的抗原结合多肽及其应用
JP2018535701A5 (cg-RX-API-DMAC7.html)
JP2021500881A5 (cg-RX-API-DMAC7.html)
JP2023552998A (ja) 効力および持続性の増強のために免疫細胞を操作する方法、ならびに免疫療法における操作された細胞の使用
JP2022520455A5 (cg-RX-API-DMAC7.html)
JP2023519346A5 (cg-RX-API-DMAC7.html)
KR20230066007A (ko) 신규한 보조자극 도메인을 포함하는 키메라 항원 수용체 및 이의 용도
US20230051885A1 (en) Systems and Methods for Producing Efficacious Regulatory T Cells
JP2023553390A5 (cg-RX-API-DMAC7.html)
JP2022513372A5 (cg-RX-API-DMAC7.html)
US20250230410A1 (en) Chimeric antigen receptors with enhanced signaling and activities and uses thereof
JP2022546577A5 (cg-RX-API-DMAC7.html)
JP2020500903A5 (cg-RX-API-DMAC7.html)